Skip to main content

Table 3 Items included in the questionnaire about “Olive and grass pollen allergy” (3A) and results (3B)

From: Diagnosis and allergen immunotherapy treatment of polysensitised patients with respiratory allergy in Spain: an Allergists’ Consensus

3A) 3B)
Items Mean Median % Panellists IQ Result
Epidemiology
51- All olive-grass cosensitised patients are equal if they are from the same geographic area 2.15 2 9.68 2 D
52- All olive-grass cosensitised patients are equal if they have the same size wheals 1.84 1 4.84 1.5 D
53- The genuine sensitisation components (Phl p 1–5 and Ole e 1) are suitable for identifying phenotypes 7.1 7 11.29 1 A
Clinical relevance
54- Geographic and aerobiological data are very important in identifying the clinical relevance of olive and grass cosensitised patients 7.29 7 11.29 1 A
55- In olive-grass cosensitised patients, skin-tests have major limitations in confirming the clinical relevance 7.18 7.5 16.13 1 A
56- A higher level of olive IgE than grass (or vice versa) is useful to highlight the clinical relevance in cosensitised patients 4.08 3 45 2 NC
57- Confirmation of true sensitisation to olive or grass requires an IgE against genuine components 7.56 8 8.06 1 A
58- The clinical relevance in olive-grass cosensitised patients can only be defined by organ-specific provocation tests 3.19 3 25.81 2 D
Therapeutic strategy (Immunotherapy indication)
59- The identification of the relevant allergenic source in patients cosensitised to grass and olive is essential before prescribing immunotherapy 7.98 8 4.84 1 A
60- The demonstrated efficacy in grass immunotherapy is the same as 50% mixture with olive 2.92 3 20 1 D
61- In the case of olive-grass cosensitised patients, it is preferable to formulate personalised mixes (variable percentages of the two extracts) 4.52 5 71.67 4 NC
62- As grass and olive are complex extracts, the dosage of individual allergens in immunotherapy would be appropriate 7.05 7 10 1 A
63- The olive-grass cosensitised patient should not receive immunotherapy until more efficacy data is obtained 2.55 2 14.52 2 D
Therapeutic strategy (Immunotherapy formulation)
64- The lack of knowledge of therapeutic doses makes the formulation of mixtures difficult 6.82 7 27.42 2 A
65- It is correct to formulate olive-grass personalised mixes depending on the size of the wheal 2.53 2 22.58 2 D
66- It is preferable to formulate olive-grass personalised mixes (varying percentages of the two extracts) in proportion to the IgE amount corresponding to the two extracts 3.72 3 46.67 3.5 NC
67- If the manufacturer guarantees the individual doses of allergens, mixtures of different Poaceae and olive varieties are irrelevant 6.95 7 23.33 1 A
68- Grass and olive personalised mixtures (varying percentages of the two extracts) should never be used 3.92 3 30 2 D
  1. A = Agreement; D = Disagreement; NC = No Consensus; IQ = Interquartile range.
  2. % panellists = percentage of panellists out of the median region.